Psychedelic Medicine
June 1, 2024
Ryan Yermus, John Bottos, Nathan Bryson et al.
13 citations
Ketamine-assisted psychotherapy (KAP) is an emerging treatment option to alleviate treatment-resistant affective disorders, but its long-term effectiveness remains unclear. To examine the treatment effects of KAP on anxiety, depression, and post-traumatic stress disorder (PTSD) at 1, 3, and 6 months post-treatment. This retrospective effectiveness study included self-reported outcomes from...
Psychological Medicine
June 1, 2024
Balázs Szigeti, Brandon Weiss, Fernando E. Rosas et al.
74 citations
To investigate the association between pre-trial expectancy, suggestibility, and response to treatment in a trial of escitalopram and investigational drug, COMP360, psilocybin, in the treatment of major depressive disorder (ClinicalTrials.gov registration: NCT03429075). We used data (n = 55) from our recent double-blind, parallel-group, randomized head-to-head comparison trial of escitalopram...
The Nursing clinics of North America
June 1, 2024
David Agor, Brandon A Knettel, Kenneth Daici et al.
2 citations
The transition of HIV into a chronic illness has brought to the forefront the pressing need to address the complex web of social determinants of HIV outcomes. A structured literature search and narrative review of studies describing intervention strategies for mental health among sexual/gender minority (SGM) older adults living with HIV (OALWH) published in the last decade identified 2 studies...
Clinical Psychopharmacology and Neuroscience
May 31, 2024
Alessandro Serretti
8 citations
For the first time after many decades, many new antidepressants have been approved and many more are under various stages of development and will soon be available in the market. The new drugs present a range of new mechanisms of action with benefits in terms of speed of action, tolerability and range of treatable disorders. Neurosteroids have been recently approved and their rapid benefit may...
Healthcare
May 30, 2024
Marc Dörner, Roland Von Känel, Noelle König et al.
5 citations
Several studies suggested the efficacy of dispositional mindfulness and mindfulness-based interventions in reducing anxiety and depression in cardiovascular diseases. However, data on the impact of mindfulness on the psychological well-being of patients with an implantable cardioverter-defibrillator (ICD) are scarce. In this study, 422 patients with an ICD were prospectively recruited. Logistic...
Journal of Clinical and Experimental Neuropsychology
May 27, 2024
Laura Ramos, Selene G Vicente
5 citations
Psilocybin acutely alters several cognitive domains, with a localized rather than global focus, in a dose- and time-dependent manner. However, the significant methodological constraints call for further research, in the context of depression and with standardized protocols, with longitudinal studies also imperative.
May 23, 2024
Daniël Hoyer
There is controversy about a causal role of serotonin (5-HT) in depression, some arguing that there is no proof for impaired brain 5-HT function in depressed patients. Major depressive disorder comes with multiple endophenotypes; not surprisingly classical antidepressants (tricyclics, MAO inhibitors, SSRIs, SNRIs) are not universally effective. Most antidepressants target the 5-HT system,...
Molecules
May 23, 2024
Shiyun Li, Bin Wen, Wei Zhao et al.
4 citations
Depression is a chronic, severe, and often life-threatening neurological disorder. It not only causes depression in patients and affects daily life but, in severe cases, may lead to suicidal behavior and have adverse effects on families and society. In recent years, it has been found that sub-anesthetic doses of ketamine have a rapid antidepressant effect on patients with treatment-resistant...
Trials
May 21, 2024
Chiranth Bhagavan, Paul Glue, Will Evans et al.
7 citations
Symptoms of anxiety and depression are common in patients with terminal illness and multiple challenges exist with timely and effective care in this population. Several centres have reported that one dose of the serotonergic psychedelic psilocybin, combined with therapeutic support, improves these symptoms for up to 6 months in this patient group. Drawing upon related therapeutic mechanisms,...
European Journal of Neuroscience
May 21, 2024
Nur Damla Korkmaz, Ugur Cikrikcili, Merve Akan et al.
19 citations
Abstract Psychoactive substances obtained from botanicals have been applied for a wide variety of purposes in the rituals of different cultures for thousands of years. Classical psychedelics from N,N′‐dimethyltryptamine, psilocybin, mescaline and various lysergamides cause specific alterations in perception, emotion and cognition by acting through serotonin 5‐HT 2A receptor activation. Lysergic...
Ganaya
May 20, 2024
Maisi Yantina, Roswiyani Roswiyani, Riana Sahrani
Primiparous mothers, women who are giving birth for the first time, face challenges in adapting to a new postpartum role as a mother. Due to the pressure they are under, they are more likely to suffer from psychological issues including anxiety and depression. The purpose of this study is to ascertain how maternal self-efficacy affects mindfulness and postpartum depression in primiparous...
Philosophical Psychology
May 20, 2024
Dan Degerman
Despite the relevance of silence in several psychopathologies, first-person perspectives on silence have been largely neglected in the phenomenological scholarship on those conditions. This paper proposes a phenomenological framework for addressing this neglect and demonstrates its usefulness through a case study of empty silence, an experience which can be found in many first-person accounts...
The British Journal of Psychiatry
May 20, 2024
David Nutt, Ilana B Crome, Allan H. Young
18 citations
Australia has just rescheduled two drugs controlled under the United Nations Psychotropic Drug Conventions, psilocybin and MDMA, as treatments for treatment-resistant depression and post-traumatic stress disorder respectively. This feature explores the reasons for these developments, the opportunities and challenges they provide to psychiatry communities and how along with health systems these...
Journal of Happiness and Health
May 19, 2024
Bridget Kennedy, Nicholas Sims-Rhodes, Jacob Avendano et al.
Mental health research is often focused on alleviating psychological distress rather than increasing well-being. This study approached mental health from a dual-continua model (DCM) framework, which allows for distress and well-being to co-occur. The aims of the present study were to expand upon DCM literature by examining differences in psychological well-being indicators among a broad adult...
Journal of Education, Health and Sport
May 15, 2024
Mateusz Pawlicki, Aleksandra Kłos, Karol Stachyrak et al.
Introduction: Mental disorders are common and still growing problem around the globe. Significantly decreasing quality of life, they are often source of true suffering for patients and their families leading to further health issues or even dramatic outcomes resulting in death. As public awareness rises, more and more people understand risks and tend to look for help as fast as possible....
Neuroscience Letters
May 14, 2024
Daniele Cavaleri, Ilaria Riboldi, Cristina Crocamo et al.
13 citations
The antidepressant effects of ketamine and esketamine are well-documented. Nonetheless, most of the underlying molecular mechanisms have to be uncovered yet. In the last decade, metabolomics has emerged as a useful means to investigate the metabolic phenotype associated with depression as well as changes induced by antidepressant treatments. This mini-review aims at summarizing the main...
Psychopharmacology
May 14, 2024
Mazen A Atiq, Matthew R Baker, Jennifer L. Vande Voort et al.
12 citations
Recent research with classic psychedelics suggests significant therapeutic potential, particularly for neuropsychiatric disorders. A mediating influence behind symptom resolution is thought to be the personal insight - at times, bordering on the mystical - one acquires during the acute phase of a psychedelic session. Indeed, current clinical trials have found strong correlations between the...
Jurnal Psikiatri Surabaya
May 13, 2024
Satrio Wahyu Nugroho, Agustina Konginan, Gadis Meinar Sari et al.
1 citation
Introductions: In Indonesia, a median of 6.1% of people diagnosed with depression disorder are people over 15 years old. Only 9% of that amount underwent medical treatment, while the rest, 91%, did not undergo treatment for their depressive conditions. Inadequate and inappropriate treatment of depression will lead to Treatment-Resistant Depression (TRD). Using ketamine as a pharmacotherapy...
International Journal of Innovative Science and Research Technology
May 11, 2024
Shreyas. Y. Bobade, V.V. Paithankar, J.V. Vyas et al.
The Indian pharmaceutical industry is one of the fastest-growing sectors of the Indian economy and ranks among the top 15 drug-manufacturing countries globally. Among the fastest-growing industries in the world, the pharmaceutical industry has increased over the years. A pharmaceutical company appoints a medical representative to make their products easily reach healthcare specialists and then...
Frontiers in Psychiatry
May 10, 2024
Qin Xiang Ng, Yu Liang Lim, Clarence Ong et al.
3 citations
Objective: To investigate societal perceptions of ketamine's use in depression therapy by analysing Twitter posts from January 1, 2010 to April 1, 2023. Methods: Using Twitter as the social media platform of choice, and employing search terms based on (depression OR depressed OR depressive) AND (ketamine OR esketamine OR Spravato), we collected English-language tweets from January 1, 2010, to...